A Full Face Study to Evaluate the Efficacy of Dermapen 4™ Microneedling Device in Addition with MG-CLR Serum for Acne Treatment Over 12 Weeks.

A Full Face, Baseline Controlled Study to Evaluate the Efficacy of Dermapen 4™ Microneedling Device in Conjunction with MG-CLR Serum for Acne Treatment Over 12 Weeks.

Status

Not yet recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06602284

Enrollment

Registered

2024-09-19

Start date

2024-10-31

Completion date

2025-03-31

Last updated

2024-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne

Keywords

dermapen, microneedling, acne

Brief summary

This study is conducted to check how well the Dermapen 4™ microneedling device works with MG-CLR serum for treating acne over 12 weeks.

Interventions

COMBINATION_PRODUCTDermapen 4™

Dermapen 4™ conjunction with MG-CLR

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

1. Female subjects aged between 18-45 years (both ages inclusive) 2. Fitzpatrick skin phototype I to VI. 3. Subjects having IGA score of 2 and 3. 4. Subjects who have not received any kind of treatment for acne 1 month before the start of the study. 5. Subject free of excessive hair, cuts, abrasions, fissures, wounds, lacerations, or any other skin conditions on the face. 6. Subjects who agree not to use any other product/treatment/home remedy/ except the provided products on their face during the study period

Exclusion criteria

1. Subjects with known skin condition that may impact the assessment. 2. Subjects with active Herpes labialis infection. 3. Subjects known to have bleeding and clotting disorders (self-declared). 4. Subjects known to have connective tissue disorders. 5. Subjects with any other signs of significant local irritation or skin disease. 6. Subjects currently taking any medication, which the investigator believes may influence the interpretation of the data.

Design outcomes

Primary

Measure	Time frame	Description
Acne severity	13 weeks	Change in acne severity using the modified GAGS scale at all time points when compared to baseline.

Countries

United States

Contacts

Primary ContactStene Marshal

stene@dermapenworld.com(949) 798 6207

Backup ContactAahan Sachdev

aahan.sachdev@msclinical.com9880755883

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026